6 Analysts Have This to Say About CymaBay Therapeutics
Portfolio Pulse from Benzinga Insights
Over the last quarter, CymaBay Therapeutics (NASDAQ:CBAY) received 6 analyst ratings, with 4 being bullish and 2 somewhat bullish. There were no indifferent, somewhat bearish, or bearish ratings. The average 12-month price target for CBAY is $28.0, with a high of $34.00 and a low of $24.00, marking a 21.74% increase from the previous target of $23.00. Analysts use various methods to determine their ratings, and while their opinions are influential, they are also subjective.
December 15, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CymaBay Therapeutics received positive ratings from analysts, with an increased average price target of $28.0, suggesting a bullish outlook for the stock.
The unanimous bullish and somewhat bullish ratings from analysts, combined with an increased price target, are likely to generate positive sentiment among investors, potentially driving the stock price up in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100